Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011 – 2014)

Bibliography

• Asahchop EL, Wainberg MA, Sloan RD, et al. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother 2012;56:5000-8
   PubMed Web of Science ®Google Scholar
• Reynolds C, de Koning CB, Pelly SC, et al. In search of a treatment for HIV-current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Chem Soc Rev 2012;41:4657-70
   PubMed Web of Science ®Google Scholar
• Jayaweera D, Dilanchian P. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data. Expert Opin Pharmacother 2012;13:2601-12
   PubMed Web of Science ®Google Scholar
• Rawal RK, Murugesan V, Katti SB. Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs. Curr Med Chem 2012;19:5364-80
   PubMed Web of Science ®Google Scholar
• Available from: http://aidsinfo.nih.gov/guidelines
   Google Scholar
• Available from: www.who.int/hiv/pub/guidelines/en/
   Google Scholar
• Available from: www.eacsociety.org/Guidelines.aspx
   Google Scholar
• Available from: www.iasusa.org/guidelines-archive
   Google Scholar
• Croxtall JD. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection. Drugs 2012;72:847-69
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Short WR. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review. Antivir Ther 2012;17:1495-502
   PubMed Web of Science ®Google Scholar
• Li D, Zhan P, De Clercq E, et al. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. J Med Chem 2012;55:3595-613
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. Curr Med Chem 2009;16:2876-89
   PubMed Web of Science ®Google Scholar
• Song Y, Fang Z, Zhan P, et al. Recent Advances in the Discovery and Development of Novel HIV-1 NNRTI Platforms (Part II): 2009-2013 Update. Curr Med Chem 2013;21:329-55
   Web of Science ®Google Scholar
• Zhan P, Chen X, Li D, et al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 2013;33:E1-E72
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). Expert Opin Ther Pat 2011;21:717-96
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z, et al. Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem 2009;16:3903-17
   PubMed Web of Science ®Google Scholar
• Heil ML, Cosford Nicholas DP, Pagano N, et al. Preparation of 5-(thiazol-2-yl)-3,4-dihydropyrimidones as HIV replication inhibitors useful in the treatment of HIV infections. WO2013033003A1; 2013
   Google Scholar
• Kim J, Cechetto J, No Z, et al. Preparation of substituted biaryl and arylheteroaryl derivatives as antiviral agents. WO2010046780A2; 2010
   Google Scholar
• Thede K, Greschat S, Wildum S, et al. Preparation of pyrazolylcarbonylimidazolidinones as antiviral agents. WO2009115213A1; 2009
   Google Scholar
• Verhoeven E, Voorspoels J, Gonnissen Y, et al. Solid dispersion comprising a chlorofluorophenyl pyrazolylcarbonyl imidazolidinone anti-HIV agent. WO2011029909A1; 2011
   Google Scholar
• Jorgensen WL, Anderson KG. Preparation of catechol diethers as anti-HIV agents. WO2013056003; 2013
   Google Scholar
• Li A, Wang X, Ma L, et al. Preparation of 2(1H)-pyridinone derivatives as HIV-1 reverse transcriptase inhibitors. CN102001994A; 2011
   Google Scholar
• Burch J, Cote B, Nguyen N, et al. Preparation of 1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-pyridin-2(1H)-one compounds as non-nucleoside reverse transcriptase inhibitors. WO2011120133A1; 2011
   Google Scholar
• Dunn JP, Elworthy TR, Zachary KS. Heterocyclic antiviral compounds. US2011207688; 2011
   Google Scholar
• Jolly SM, Anthony N, Gomez R, et al. Prodrugs of an HIV reverse transcriptase inhibitor. WO2011126969A1; 2011
   Google Scholar
• Ma J, Guo Y, Zhang F, et al. 4-(trans-3-Buten-1-ynyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one compounds as HIV replication inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infections. CN103524430A; 2014
   Google Scholar
• Jiang B, Zhang C, Li J, et al. Preparation of 4,4-disubstituted-dihydro-2(1H)-quinazolinone or thione-like compounds as HIV reverse transcriptase inhibitors for the treatment of HIV. CN102718721A; 2012
   Google Scholar
• Wu S, Zhou H, Tian B, et al. Preparation of indole derivatives as HIV-1 reverse transcriptase inhibitors. CN103113285A; 2013
   Google Scholar
• Jiang B, Zhang C, Li J, et al. Preparation of indole derivatives as HIV reverse transcriptase inhibitors. CN102675280A; 2012
   Google Scholar
• Jiang B, Zhang C, Jiang H, et al. Preparation of indole derivatives as HIV reverse transcriptase inhibitors. CN102766083A; 2012
   Google Scholar
• Zhang L, Wang R, Wang X, et al. 1,5,6-Substituted pyrimidine derivatives with anti-HIV virus activity and their preparation, pharmaceutical compositions and use in the treatment of AIDs. CN102838549A; 2012
   Google Scholar
• Wang X, Zhang J, Liu J. Uracil derivatives as HIV-1 reverse transcriptase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of AIDs. CN102295608A; 2011
   Google Scholar
• Zhang S, Wang X, Fang X, et al. 6-Cyclohexylmethyl-2-aromatic ring carbonyl-substituted N-DABO-like compounds, their synthetic method and application as anti-HIV agents. CN103288747A; 2013
   Google Scholar
• Liu X, Zhang J, Zhan P. 2-Aryl methylthio-6-(tetrahydroquinolin-1-ylmethyl)-4-pyrimidone derivatives useful in the treatment of HIV-1 and their preparation. CN102285967A; 2011
   Google Scholar
• Liu C, Liu J. Preparation of 6-(1-naphthalenylmethyl)-4(3H)-pyrimidinone derivatives as HIV-1 reverse transcriptase inhibitors. CN102134223A; 2011
   Google Scholar
• Liu X, Tian Y, Zhan P. Preparation of thiadiazine derivatives as anti-HIV agents. CN102775371A; 2012
   Google Scholar
• Arrington KL, Burgey C, Gilfillan R, et al. Preparation of pyrimidinyl non-nucleoside reverse transcriptase inhibitors for treatment of HIV infection and AIDS. US20140100231A1; 2014
   Google Scholar
• Huang X, Zhang B. Method for synthesizing pyridone lead compounds as non-nucleoside HIV inhibitors. CN103288719A; 2013
   Google Scholar
• Rios A. Inactivation of reverse transcriptases by azidodiarylpyrimidines. WO2011109697A1; 2011.US2011217331; 2011
   Google Scholar
• Chen F, Yan Z, He Q. Preparation of diaryl pyrimidine derivatives useful in the treatment of HIV infection. CN103787985A; 2014
   Google Scholar
• Liu X, Chen X, Zhan P. N-1-substituted piperidine-4-arylamine derivative useful in the treatment of HIV infection and its preparation. CN102285969A; 2011
   Google Scholar
• Liu X, Zhang L. Preparation of 2-(N-arylmethylpiperidine-4-ylamino)-4-(substituted-phenoxy)benzene derivatives as HIV-1 inhibitors. CN103497146A; 2014
   Google Scholar
• Xie L, Chen CH, Sun L, et al. Preparation of diarylaniline or diarylpyridinamine derivatives as anti-HIV agents. WO2014012467A1; 2014
   Google Scholar
• Franck P, Heeres J, Maes B, et al. Preparation of fluoroaromatic derivatives useful as anti-HIV compounds. WO2014072419A1; 2014
   Google Scholar
• Liu X, Li D, Zhan P. Pyridazine derivatives as HIV-1 reverse transcriptase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of AIDs. CN102731410A; 2012
   Google Scholar
• Liu X, Li X, Zhan P. m-Diarene-pyrimidine derivatives as HIV-1 reverse transcriptase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infection. CN103483272A; 2014
   Google Scholar
• Liu X, Wang L, Zhan P. Triazolopyrimidines as HIV-1 reverse transcriptase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of AIDs. CN103360398A; 2013
   Google Scholar
• Liu X, Tian Y, Zhan P. Substituted pyrazolo[1,5-a]pyrimidine derivative, its preparation method and application in preparation of drug for treatment and prevention of human immunodeficiency virus (HIV) infection. CN103570728A; 2014
   Google Scholar
• Liu X, Jiang X, Zhan P. Preparation of 1,2,3-thiadiazole derivatives for treatment of HIV infection. CN102659714A; 2012
   Google Scholar
• Liu X, Zhan P, Li X, et al. Preparation of heterocyclic compounds as anti-HIV agents. CN102276535A; 2011
   Google Scholar
• Liu X, Zhan P, Li X. Preparation of six-membered heteroaryl fused imidazole thioacetamide derivatives as anti-HIV agents. CN102516244A; 2012
   Google Scholar
• Liu X, Chen W, Zhan P. N2,N4-Bis-substituted-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiotriazine-1,1,3-trione derivatives useful in the treatment of AIDS and their preparation. CN102321102A; 2012
   Google Scholar
• Guo C, Guo Y, Li Z, et al. Preparation of thiazole derivatives as anti-HIV agents. CN103159695A; 2013
   Google Scholar
• Heeres J, Van Der Veken P, Joossens J, et al. Triazines with suitable spacers for treatment and/or prevention of HIV infections and their preparation. WO2013139727A1; 2013
   Google Scholar
• Radi M, Botta M, Angeli L, et al. Crystal structure of HIV-1 reverse transcriptase bound to a nucleotide-competitive reverse transcriptase inhibitor and its use for the design and identification of inhibitors. WO2011073959A2; 2011
   Google Scholar
• Kim J, Park C, Ok T, et al. Discovery of 3,4-dihydropyrimidin-2(1H)-ones with inhibitory activity against HIV-1 replication. Bioorg Med Chem Lett 2012;22:2119-24
   PubMed Web of Science ®Google Scholar
• Kim J, Ok T, Park C, et al. A novel 3,4-dihydropyrimidin-2(1H)-one: HIV-1 replication inhibitors with improved metabolic stability. Bioorg Med Chem Lett 2012;22:2522-6
   PubMed Web of Science ®Google Scholar
• Kim J, Lee D, Park C, et al. Discovery of phenylaminopyridine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. ACS Medicinal Chemistry Letters 2012;3:678-82
   PubMed Web of Science ®Google Scholar
• Wildum S, Paulsen D, Thede K, et al. In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2013;57:5320-9
   PubMed Web of Science ®Google Scholar
• Kim TH, Ko Y, Christophe T, et al. Identification of a novel sulfonamide non-nucleoside reverse transcriptase inhibitor by a phenotypic HIV-1 full replication assay. PLoS One 2013;8:e68767
   PubMed Web of Science ®Google Scholar
• Chen L, Ao Z, Jayappa KD, et al. Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection. Antimicrob Agents Chemother 2013;57:3547-54
   PubMed Web of Science ®Google Scholar
• Nichols SE, Domaoal RA, Thakur VV, et al. Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures. J Chem Inf Model 2009;49:1272-9
   PubMed Web of Science ®Google Scholar
• Bollini M, Domaoal RA, Thakur VV, et al. Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J Med Chem 2011;54:8582-91
   PubMed Web of Science ®Google Scholar
• Frey KM, Bollini M, Mislak AC, et al. Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design. J Am Chem Soc 2012;134:19501-3
   PubMed Web of Science ®Google Scholar
• Ivetac A, Swift SE, Boyer PL, et al. Discovery of novel inhibitors of HIV-1 reverse transcriptase through virtual screening of experimental and theoretical ensembles. Chem Biol Drug Des 2014;83:521-31
   PubMed Web of Science ®Google Scholar
• García-Sosa AT, Sild S, Takkis K, et al. Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase. J Chem Inf Model 2011;51:2595-611
   PubMed Web of Science ®Google Scholar
• Frey KM, Gray WT, Spasov KA, et al. Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase. Chem Biol Drug Des 2014;83:541-9
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Schyman P. Treatment of halogen bonding in the OPLS-AA force field; application to potent anti-HIV agents. J Chem Theory Comput 2012;8:3895-01
   PubMed Web of Science ®Google Scholar
• Zimmermann MO, Lange A, Wilcken R, et al. Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery. Future Med Chem 2014;6:617-39
   PubMed Web of Science ®Google Scholar
• Wilcken R, Zimmermann MO, Lange A, et al. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J Med Chem 2013;56:1363-88
   PubMed Web of Science ®Google Scholar
• Lu Y, Liu Y, Xu Z, et al. Halogen bonding for rational drug design and new drug discovery. Expert Opin Drug Discov 2012;7:375-83
   PubMed Web of Science ®Google Scholar
• Lian J, Wang J, Sun HF, et al. Application of methyl in drug design. Yao Xue Xue Bao 2013;48:1195-208
   PubMedGoogle Scholar
• Leung CS, Leung SS, Tirado-Rives J, et al. Methyl effects on protein-ligand binding. J Med Chem 2012;55:4489-500
   PubMed Web of Science ®Google Scholar
• Fleming FF, Yao L, Ravikumar PC, et al. Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. J Med Chem 2010;53:7902-17
   PubMed Web of Science ®Google Scholar
• Lyn HJ, Nicholas WS, Nigel AS, et al. Aromatic chloride to nitrile transformation: medicinal and synthetic chemistry. Med Chem Commun 2010;1:309-18
   Google Scholar
• Jorgensen WL, Bollini M, Thakur VV, et al. Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. J Am Chem Soc 2011;133:15686-96
   PubMed Web of Science ®Google Scholar
• Bollini M, Gallardo-Macias R, Spasov KA, et al. Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency. Bioorg Med Chem Lett 2013;23:1110-13
   PubMed Web of Science ®Google Scholar
• Cole DJ, Tirado-Rives J, Jorgensen WL. Enhanced Monte Carlo sampling through replica exchange with solute tempering. J Chem Theory Comput 2014;10:565-71
   PubMed Web of Science ®Google Scholar
• Fang Z, Song Y, Zhan P, et al. Conformational restriction: an effective tactic in ’follow-on’-based drug discovery. Future Med Chem 2014;6:885-901
   PubMed Web of Science ®Google Scholar
• Rotili D, Tarantino D, Nawrozkij MB, et al. Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes. J Med Chem 2014;57:5212-25
   PubMed Web of Science ®Google Scholar
• Li A, Ouyang Y, Wang Z, et al. Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains. J Med Chem 2013;56:3593-608
   PubMed Web of Science ®Google Scholar
• Bollini M, Frey KM, Cisneros JA, et al. Extension into the entrance channel of HIV-1 reverse transcriptase–crystallography and enhanced solubility. Bioorg Med Chem Lett 2013;23:5209-12
   PubMed Web of Science ®Google Scholar
• Bollini M, Cisneros JA, Spasov KA, et al. Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility. Bioorg Med Chem Lett 2013;23:5213-16
   PubMed Web of Science ®Google Scholar
• Mislak AC, Frey KM, Bollini M, et al. A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase. Biochim Biophys Acta 2014;1840:2203-11
   PubMed Web of Science ®Google Scholar
• Paul B, Hawa D, Jonathan DG, et al. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. J Med Chem 2012;55:587-96
   PubMed Web of Science ®Google Scholar
• Skoda EM, Sacher JR, Kazancioglu MZ, et al. An uncharged oxetanyl sulfoxide as a covalent modifier for improving aqueous solubility. ACS Med Chem Lett 2014;5:900-4
   PubMed Web of Science ®Google Scholar
• Lai MT, Feng M, Falgueyret JP, et al. In vitro characterization of MK-1439: A novel HIV-1 non-nucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2014;58:1652-63
   PubMed Web of Science ®Google Scholar
• Côté B, Burch JD, Asante-Appiah E, et al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett 2014;24:917-22
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Oishi S, Kaneda M, et al. Kinesin spindle protein inhibitors with diaryl amine scaffolds: crystal packing analysis for improved aqueous solubility. ACS Med Chem Lett 2014;5:566-71
   PubMed Web of Science ®Google Scholar
• Timmins P, Brown J, Meanwell NA, et al. Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery. Drug Discov Today 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• David KL, Shawn KP. Preparation of phosphonooxymethyl prodrugs of HIV-1 attachment inhibitors. Org Process Res Dev 2013;17:1440-4
   Web of Science ®Google Scholar
• Kadow JF, Ueda Y, Meanwell NA, et al. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043). J Med Chem 2012;55:2048-56
   PubMed Web of Science ®Google Scholar
• Oslob JD, Heumann SA, Yu CH, et al. Water-soluble prodrugs of an Aurora kinase inhibitor. Bioorg Med Chem Lett 2009;19:1409-12
   PubMed Web of Science ®Google Scholar
• Ueda Y, Matiskella JD, Golik J, et al. Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties. Bioorg Med Chem Lett 2003;13:3669-72
   PubMed Web of Science ®Google Scholar
• Liu Y, Hong L, Yu LS, et al. The role of ADME evaluation in translation research of innovative drug. Yao Xue Xue Bao 2011;46:19-29
   PubMedGoogle Scholar
• Lee WG, Gallardo-Macias R, Frey KM, et al. Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group. J Am Chem Soc 2013;135:16705-13
   PubMed Web of Science ®Google Scholar
• Liu N, Qin B, Sun LQ, et al. Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett 2014;24:3719-23
   PubMed Web of Science ®Google Scholar
• Wu ZY, Liu N, Qin B, et al. Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS. ChemMedChem 2014;9:1546-55
   PubMed Web of Science ®Google Scholar
• Sun LQ, Zhu L, Qian K, et al. Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. J Med Chem 2012;55:7219-29
   PubMed Web of Science ®Google Scholar
• Kang D, Song Y, Chen W, et al. "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets. Mol Biosyst 2014;10:1998-2022
   PubMed Web of Science ®Google Scholar
• Jiang HX, Zhuang DM, Huang Y, et al. Design, synthesis, and biological evaluation of novel trifluoromethyl indoles as potent HIV-1 NNRTIs with an improved drug resistance profile. Org Biomol Chem 2014;12:3446-58
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang J, Huang Y, et al. Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. J Med Chem 2012;55:2242-50
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Lu LH, Wang RR, et al. DB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOs. PLoS One 2013;8:e81489
   Web of Science ®Google Scholar
• Zhang J, Zhan P, Wu J, et al. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 2011;19:4366-76
   PubMed Web of Science ®Google Scholar
• Zhang L, Tang X, Cao Y, et al. Synthesis and biological evaluation of novel 2-arylalkylthio-5-iodine-6-substituted-benzyl-pyrimidine-4(3H)-ones as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Molecules 2014;19:7104-21
   PubMed Web of Science ®Google Scholar
• Tian Y, Rai D, Zhan P, et al. Design, synthesis, and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs. Chem Biol Drug Des 2013;82:384-93
   PubMed Web of Science ®Google Scholar
• Yan ZH, Wu HQ, Chen WX, et al. Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem 2014;22:3220-6
   PubMedGoogle Scholar
• Yan ZH, Huang XY, Wu HQ, et al. Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem 2014;22:2535-41
   PubMed Web of Science ®Google Scholar
• Chen X, Zhan P, Liu X, et al. Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem 2012;20:3856-64
   PubMed Web of Science ®Google Scholar
• Chen X, Zhan P, Pannecouque C, et al. Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. Eur J Med Chem 2012;51:60-6
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhan P, Chen X, et al. Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. Bioorg Med Chem 2014;22:633-42
   PubMed Web of Science ®Google Scholar
• Li D, Zhan P, Liu H, et al. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorg Med Chem 2013;21:2128-34
   PubMed Web of Science ®Google Scholar
• Wang J, Zhan P, Li Z, et al. Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. Eur J Med Chem 2014;76:531-8
   PubMed Web of Science ®Google Scholar
• Li X, Chen W, Tian Y, et al. Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. Eur J Med Chem 2014;80:112-21
   PubMed Web of Science ®Google Scholar
• Tian Y, Du D, Rai D, et al. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. Bioorg Med Chem 2014;22:2052-9
   PubMed Web of Science ®Google Scholar
• Wang L, Tian Y, Chen W, et al. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. Eur J Med Chem 2014;85C:293-303
   Google Scholar
• Zhan P, Li Z, Liu X, et al. Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs. Mini Rev Med Chem 2009;9:1014-23
   PubMed Web of Science ®Google Scholar
• Song Y, Zhan P, Liu X. Heterocycle-thioacetic acid motif: a privileged molecular scaffold with potent, broad-ranging pharmacological activities. Curr Pharm Des 2013;19:7141-54
   PubMed Web of Science ®Google Scholar
• Zhan P, Chen W, Li Z, et al. Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach. Bioorg Med Chem 2012;20:6795-802
   PubMed Web of Science ®Google Scholar
• Zhan P, Li X, Li Z, et al. Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. Bioorg Med Chem Lett 2012;22:7155-62
   PubMed Web of Science ®Google Scholar
• Song Y, Zhan P, Kang D, et al. Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. Med Chem Commun 2013;4:810-16
   Google Scholar
• Li X, Zhan P, Liu H, et al. Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorg Med Chem 2012;20:5527-36
   PubMed Web of Science ®Google Scholar
• Li X, Lu X, Chen W, et al. Arylazolyl(azinyl)thioacetanilides. Part 16: structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. Bioorg Med Chem 2014;19:5209-7
   Google Scholar
• Zhan P, Liu X, De Clercq E. Recent advances in antiviral activity of benzo/heterothiadiazine dioxide derivatives. Curr Med Chem 2008;15:1529-40
   PubMed Web of Science ®Google Scholar
• Chen W, Zhan P, De Clercq E, et al. Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b] [1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. Bioorg Med Chem 2013;21:7091-100
   PubMedGoogle Scholar
• Chen W, Zhan P, Rai D, et al. Facile synthesis of derivatives of 1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine: a new heterocyclic system. Heteroatom Chem 2013;24:495-501
   Web of Science ®Google Scholar
• Li X, Zhan P, De Clercq E, et al. The HIV-1 non-nucleoside reverse transcriptase inhibitors (Part V*): capravirine and its analogues. Curr Med Chem 2012;19:6138-49
   PubMed Web of Science ®Google Scholar
• Xu Z, Ba M, Zhou H, et al. 2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase. Eur J Med Chem 2014;85C:27-42
   Google Scholar
• Stumpfe D, Hu Y, Dimova D, et al. Recent progress in understanding activity cliffs and their utility in medicinal chemistry. J Med Chem 2014;57:18-28
   PubMed Web of Science ®Google Scholar
• Stumpfe D, Bajorath J. Exploring activity cliffs in medicinal chemistry. J Med Chem 2012;55:2932-42
   PubMed Web of Science ®Google Scholar
• Dimova D, Stumpfe D, Bajorath J. A method for the evaluation of structure-activity relationship information associated with coordinated activity cliffs. J Med Chem 2014;57(15):6553-63
   PubMed Web of Science ®Google Scholar
• Fetherston SM, Geer L, Veazey RS, et al. Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. J Antimicrob Chemother 2013;68:394-403
   PubMed Web of Science ®Google Scholar
• Ariën KK, Venkatraj M, Michiels J, et al. Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission. J Antimicrob Chemother 2013;68:2038-47
   PubMed Web of Science ®Google Scholar
• Grammen C, Ariën KK, Venkatraj M, et al. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Antiviral Res 2014;101:113-21
   PubMed Web of Science ®Google Scholar
• Rajotte D, Tremblay S, Pelletier A, et al. Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series. Antimicrob Agents Chemother 2013;57:2712-18
   PubMed Web of Science ®Google Scholar
• James CA, DeRoy P, Duplessis M, et al. Nucleotide competing reverse transcriptase inhibitors: discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors. Bioorg Med Chem Lett 2013;23:2781-6
   PubMed Web of Science ®Google Scholar
• Tremblay M, Bethell RC, Cordingley MG, et al. Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors. Bioorg Med Chem Lett 2013;23:2775-80
   PubMed Web of Science ®Google Scholar